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Innate immunity was for a long time considered to be non-speciﬁc because the major function of
this system is to digest pathogens and present antigens to the cells involved in acquired immunity.
However, recent studies have shown that innate immunity is not non-speciﬁc, but is instead sufﬁ-
ciently speciﬁc to discriminate self from pathogens through evolutionarily conserved receptors,
designated Toll-like receptors (TLRs). Indeed, innate immunity has a crucial role in early host
defence against invading pathogens. Furthermore, TLRs were found to act as adjuvant receptors
that create a bridge between innate and adaptive immunity, and to have important roles in the
induction of adaptive immunity. This paradigm shift is now changing our thinking on the pathogen-
esis and treatment of infectious, immune and allergic diseases, as well as cancers. Besides TLRs,
recent ﬁndings have revealed the presence of a cytosolic detector system for invading pathogens.
I will review the mechanisms of pathogen recognition by TLRs and cytoplasmic receptors, and
then discuss the roles of these receptors in the development of adaptive immunity in response to
viral infection.
Keywords: Toll-like receptor; signalling pathway; dendritic cell; inﬂuenza virus; interferon
1. HISTORY OF IMMUNOLOGY
Vaccination was started by Edward Jenner based on
the common observation that milkmaids who had suf-
fered from cowpox were protected against smallpox: he
used a cowpox vaccine to immunize humans against
smallpox. In 1796, Jenner inoculated cowpox pus
into the arm of a young boy. The boy became mildly
ill with cowpox but soon recovered. Later, the boy
was challenged with smallpox but showed no signs of
infection. These ﬁndings showed that infection with
cowpox could provide immunity against smallpox.
The word ‘vaccination’, which was coined by Jenner
for his treatment (from the Latin word vacca for
cow), was subsequently adopted by Louis Pasteur for
immunization against any disease. At the end of the
nineteenth century, Shibasaburo Kitasato and Emil
von Behring demonstrated the value of antitoxins in
preventing disease by producing passive immunity to
tetanus in animals that received graded injections of
blood serum from another animal infected with the
disease. This represented the ﬁrst discovery of anti-
bodies. Subsequently, Paul Ehrlich proposed his
famous side-chain theory of immunity. He believed
that toxic substances produced by bacteria bind to
cells through side-chain molecular structures
expressed on the cell surface, thereby causing disease,
and that the body produces abundant side-chains
(antibodies) in the blood to react with the speciﬁc bac-
terial toxins, thus preventing the toxins from reacting
with the side-chains of cells. This theory exactly
predicted the mechanism of antibody production from
B cells in response to antigens. Around the same
period, while studying starﬁsh larvae, Elie Metchnikoff
observed that certain white blood cells could engulf
and destroy harmful bodies, such as bacteria. Metch-
nikoff designated these cells phagocytes and the
process phagocytosis. This work shows the importance
of innate immunity in the defence against microbial
infection. Mechnikoff, together with Ehrlich, received
the Nobel Prize for Medicine for the discovery of these
two different aspects of immune responses, namely
innate immunity and humoral (adaptive) immunity,
respectively. However, humoral immunologists, in-
cluding Behring, claimed that serum rather than cells
destroyedthe invading organismsand that innateimmu-
nity cannot explain the speciﬁcity of immunity. While
humoral immunity research subsequently made remark-
able progress, innate immunity was, until recently,
regarded as an ancient and non-speciﬁc immunity that
functions in the lower animal kingdom.
2. INNATE IMMUNITY AND ADAPTIVE IMMUNITY
Immune responses are largely categorized into innate
immunity and adaptive immunity. Adaptive immunity
is further divided into humoral immunity and cellular
immunity. Humoral immunity is involved in the eradi-
cation of microbes present in the blood or ﬂuid by
generating antibodies, which are produced by B cells.
On the other hand, cellular immunity is responsible
for the eradication of cancer cells and microbes
hidden inside cells, and is mediated by killer T cells.
T and B cells express unique T-cell receptors (TCRs)
and B-cell receptors (BCRs), respectively, and recog-
nize a vast number of different antigens. TCRs and
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the differentiation of T and B cells. Each TCR and
BCR is composed of a variable region and a constant
region. The variable region is encoded by different
gene segments. Each member of the gene segment is
randomly joined to the other members, resulting in
the creation of a huge diversity of receptors. When a
huge repertoire of TCRs and BCRs is generated in a
ready-made manner, the repertoire includes receptors
that react with components of the host. Lymphocytes
harbouring self-reacting receptors are then excluded
during differentiation. When a pathogen invades the
body, T and B cells with the corresponding receptors
areactivated,andkillerTcelldevelopmentandantibody
production are induced. At the same time, memory T
and B cells are generated, allowing the host to respond
more rapidly when the same pathogen invades the body
again. Vaccination mimics an actual microbial infection
inahighlyattenuatedcondition,anditsroleistogenerate
memory cells against speciﬁc pathogens.
On the other hand, innate immunity is mediated by
leukocytes, macrophages and dendritic cells, which are
collectively called phagocytes because they engulf and
kill microbes. In the case of dendritic cells, they have
an additional role of presenting antigenic peptides
derived from microbes to T cells (ﬁgure 1). Until
recently, far less attention had been paid to the study
of innate immunity owing to its lack of speciﬁcity and
diversity in microbe recognition. Innate immunity is
found in all classes of plants and animals. For many
years, innate immunity has been considered to be a
remnant of the ancient host defence mechanism based
on the phylogenetic development of the immune
response. The cells of the innate immune system recog-
nize, and respond to, pathogens in a non-speciﬁc way.
However, unlike the adaptive immune system, they do
not confer long-lasting immunity on the host. Although
the innate immune system provides an immediate
defence against infection, it has been considered to rep-
resent a temporary system until adaptive immune
responses can be triggered. In higher organisms such
as vertebrates, innate immunity is considered to have
been replaced by adaptive immunity. However, recent
studies have shown that the innate immune system pos-
sesses a greater degree of speciﬁcity than previously
believed, and is highly developed in its ability to dis-
criminate self from foreign pathogens. This
discrimination relies to a great extent on a family of evo-
lutionarily conserved receptors, designated Toll-like
receptors (TLRs). Furthermore, there is accumulating
evidence showing that activation of innate immunity is
a prerequisite for the induction of acquired immunity.
This paradigm shift is changing our thinking on the
pathogenesis and treatment of infectious diseases,
immune diseases, allergic diseases and cancers.
According to the original theory of the immune
response, dendritic cells engulf invading pathogens,
digest them into small peptides and express the pep-
tide antigens on their cell surface. The dendritic cells
then migrate from the infected tissue to the regional
lymph nodes, where they present the antigens to
naive T cells with the corresponding receptors. In
this model, pathogen recognition takes place at the
stage of T-cell activation in the lymph nodes.
On the other hand, in the new theory, in addition to
the phagocytosis and digestion of pathogens, dendritic
cells must be activated for T-cell activation. T cells are
only activated when antigens are presented by activated
dendritic cells. In normal tissues, cells die continuously,
and the dead cells are removed by dendritic cells.
Although the resulting self antigens are presented to T
cells by the dendritic cells, the T cells do not become
activated because the dendritic cells are not activated,
thereby resulting inunresponsiveness oranergy. Forefﬁ-
cient T-cell activation, dendritic cells must be activated,
which is accompanied by the induction of costimulatory
molecules and cytokine production. Such dendritic cell
activation is mediated by TLRs.
Cancer immunotherapy has its roots in the work of
Dr William B. Coley, an American surgeon who prac-
tised in New York. In the early 1880s, he noticed that
cancers disappeared when patients experienced bac-
terial infections after surgery. Consequently, he
started to treat patients by directly injecting live Strep-
tococcus pyogenes bacteria, and later a mixture of dead
Streptococcus pyogenes and dead Serratia marcescens bac-
teria, into inoperable tumours. Although his clinical
trial achieved signiﬁcant therapeutic effects, such
treatments were not ofﬁcially approved and became
replaced by radiation therapy. Recent evidence has
indicated that these substances induce anti-tumour
immunity by activating TLRs on dendritic cells.
Although dendritic cells engulf the dead tumour cells
andpresenttheirantigenstoTcells,anti-tumour immu-
nity is not generated because the tumour cells are of self
origin and cannot activate dendritic cells. However, the
addition of microbial extracts containing TLR ligands
enables tumour antigen presentation to T cells by acti-
vated dendritic cells, which results in the induction of
effective anti-tumour immunity. A variety of bacterial
extracts and synthetic compounds that activate TLRs
are nowundergoingclinicaltrials foravarietyofcancers.
3. TOLL-LIKE RECEPTORS AND THEIR LIGANDS
TLRs are evolutionarily conserved between insects
and vertebrates. Toll, as the founder member of the
TLR family, was initially identiﬁed as an essential
developmental protein for embryonic dorsoventral
polarity in Drosophila, and was later shown to play a
critical role in the anti-fungal response of ﬂies [1].
To date, 12 members of the TLR family have been
identiﬁed in mammals [2–4]. They are type 1 integral
membrane glycoproteins, and structurally character-
ized by the presence of varying numbers of leucine-
rich repeat (LRR) motifs in the extracellular portion
as well as a cytoplasmic signalling domain homologous
to that of the interleukin (IL)-1 receptor, designated
the Toll/IL-1R (TIR) domain. The LRR domain is
important for ligand binding. The LRR domains of the
TLRs consist of 19–25 tandem copies of repeats that
are 24–29 amino acids in length and contain xLxxLxLxx
acid residues. Each unit consists of a b strand and an
a-helix connected by loops. The LRR domains of the
TLRs form a horseshoe structure and are directly
involved in ligand recognition. TLRs can recognize a
variety of components derived mainly from bacteria
and viruses (ﬁgure 2). The TLR ligands can be
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components. All TLR ligands are potent immune adju-
vants that can trigger a vigorous immune response.
Therefore, TLRs are also referred to as adjuvant
receptors. The most potent and ﬁrst identiﬁed ligand is
lipopolysaccharide (LPS). LPS is found in the outer cell
w a l l so fG r a m - n e g a t i v eb a c t e r i aa n di sr e c o g n i z e db y
TLR4 [5,6]. LPS is initially bound by a soluble factor,
LPS-binding protein, in the serum and then transferred
to target cells such as macrophages. Macrophages
express a phosphatidylinositol-anchored cell surface
molecule, cluster of differentiation 14 (CD14), which
can capture and retain LPS, which then activates
TLR4. A small secreted molecule, MD-2, is associa-
ted with TLR4 and critically involved in forming an
LPS-recognizing complex [7].
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Figure 2. TLR ligands and signalling. TLR receptors recognize different microbial components: the heterodimer of TLR4 and
MD-2 recognizes lipopolysaccharide (LPS); TLR2 recognizes triacyl and diacyl portions of lipoproteins together with TLR1
or TLR6, respectively; TLR5 recognizes ﬂagellin, a major component of ﬂagella; TLR3 recognizes double-stranded RNA;
TLR7 recognizes single-stranded RNA and TLR9 recognizes bacterial and viral DNA, the so-called CpG DNA. The signal-
ling pathways of TLRs are mediated by selective usage of adaptor molecules, MyD88, TRIF, TIRAP and TRAM. MyD88 is
involved in all TLR signalling except for TLR3. TRIF is involved in TLR3 and TLR4 dependent activation of IRF3 via IKKi/
TBK1, resulting in type 1 interferon production. TRAM is responsible for the TLR4-MyD88 dependent pathway involving
recruitment of TRIF to the cytoplasmic portion of TLR4. TIRAP is involved in recruiting MyD88 to the cytoplasmic portions
of TLR2 and TLR4. TLR7 and TLR9-dependent production of type 1 interferon requires direct interaction of MyD88 and
IRF7, which occurs only in plasmacytoid dendritic cells. Nucleic acid-recognizing TLRs (TLR3, TLR7, TLR9) are present in
the endosome.
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Figure 1. Interactions of innate and adaptive immunity. When pathogens invade the body, the innate immune system is acti-
vated ﬁrst and participates in the initial attack against the pathogens. Among the cells involved in innate immunity, dendritic
cells act as antigen-presenting cells and migrate from the infected tissue to the regional lymph nodes where they present the
antigens to T cells. Subsequently, the adaptive immune system is activated, and antibody production and killer T cells are
induced. The resulting antibodies and killer T cells speciﬁcally attack the pathogens.
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of a variety of micro-organisms are recognized by TLR2
and related TLRs, such as TLR1 and TLR6 [8–10].
HeterodimerizationiscriticalforTLR2-mediatedrecog-
nition. For example, TLR2 can recognize mycoplasma
macrophage-activating lipopeptide-2 (MALP-2) when
associated with TLR6. Meanwhile, a TLR2/TLR1
heterodimer is involved in recognizing bacterial lipopep-
tide (BLP). MALP-2 and BLP carry a diacylated and
triacylated cysteine residue at their N-terminus, respect-
ively, and this subtle difference is discriminated by the
TLR2-containing heterodimers. These receptors recog-
nizing cell wall components are expressed not only in
immune cells but also in non-immune cells, including
ﬁbroblasts, endothelial cells, adipocytes, epithelial cells
and glial cells.
In addition to cell wall components, several other
components including bacterial DNA and ﬂagellin
have immunostimulatory activity. TLR5 is involved in
recognizingﬂagellin,acomponentofthebacterialﬂagella
responsible for motility in a liquid [11]. Flagellin can
elicit mucosal immune responses by acting on epithelial
cells or macrophages. Although ﬂagellin is a protein, its
amino acid structure is highly conserved, suggesting
that it acts as a target for innate immune recognition.
TLR5 expression is observed around the body parts
that are prone to invasion by ﬂagellated bacteria, such
as the digestive tract, urinary tract and respiratory tract.
In the case of the intestinal epithelia, TLR5 expression
is conﬁned to the basolateral face and not detected on
theapicalface.Therefore,TLR5onlybecomesactivated
when ﬂagellated bacteria invade the body, such that
chemokines are produced in the epithelium and leuko-
cytes are accumulated, thereby causing inﬂammatory
responses. TLR5 is also expressed in dendritic cells
residing in the mucosa [12].
Nucleic acids are also recognized by TLRs. Bac-
terial DNA has long been known to act as a strong
immune adjuvant. This adjuvant activity is dependent
on unmethylated CpG motifs. CpG motifs are more
abundant in bacterial DNA than in mammalian
DNA. Furthermore, bacterial CpG is unmethylated
whereas mammalian CpG DNA is methylated. There-
fore, unmethylated CpG DNA can be regarded as
non-self and is recognized by TLR9 [13]. Viral DNA
is also rich in CpG motifs and DNA virus infection
triggers TLR9 signalling.
Several small synthetic molecules, including imid-
azoquinoline derivatives and several anti-cancer drugs,
are well known for their antiviral activity. This activity
is dependent on TLR7 [14]. Drugs like imidazoquin-
oline have nucleic acid-like structures, suggesting the
possibility that TLR7 is involved in the recognition of
viral RNA. Indeed, single-stranded RNA was found to
be a ligand for TLR7 and also for its close relative,
TLR8 [15,16]. These interactions are critical for sen-
sing RNA virus infection. RNA virus infection also
induces the production of double-stranded RNA
(dsRNA) in infected cells, and these dsRNAs can act
as immune adjuvants after recognition by TLR3 [17].
Importantly, TLR2 and TLR4 are mainly expressed
on the plasma membrane, while the nucleic acid-
recognizing TLRs are expressed in the endosome.
The latter is understandable because nucleic acids
are embedded inside the pathogens. In the endosome,
the nucleic acids are released from the virus or virus-
infected cells and encounter their respective TLRs.
Consistent with this, nucleic acid-recognizing TLRs
are expressed mainly in phagocytes, such as macro-
phages and dendritic cells.
4. MyD88-DEPENDENT AND -INDEPENDENT
PATHWAYS IN Toll-LIKE RECEPTOR
SIGNALLING
TLRs recognize different microbial components. Simi-
larly, the signalling pathways of individual TLRs differ
from one another. Initially, the signalling pathways of
the TLRs were thought to be identical, and to be entirely
dependent on an adaptor molecule named MyD88.
However, we noted the presence of an MyD88-indepen-
dent pathway because we found that MyD88-deﬁcient
cells could still activate nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) in response to
LPS [18]. Once the ligands of the individual TLRs had
been identiﬁed, stimulation of cells with the different
TLR ligands was found to induce distinct patterns of
gene expression, indicating differences in the signalling
pathways among the TLRs. Subsequent studies showed
that the differences in the signalling pathways among
TLRs arise through selective usage of adaptor molecules
[19,20](ﬁgure 2). MyD88 is essential for all TLR signal-
ling pathways except the TLR3 signalling pathway.
MyD88 activates NF-kB viathe IL-1 receptor-associated
kinases and TRAF6, resulting in the production of
inﬂammatory cytokines. Therefore, the MyD88-depen-
dent pathway is responsible for inﬂammatory reactions.
In addition to the MyD88-dependent pathway, there is
an MyD88-independent pathway for TLR3 and TLR4
signalling. The MyD88-independent pathway is regu-
lated by another adaptor molecule named TRIF [21].
TRIFactivatesthe transcription factor interferon regulat-
ory factor 3 (IRF3), which becomes phosphorylated and
translocates from the cytoplasm to the nucleus, resulting
intheproductionoftype1interferons(IFNs).Therefore,
the TRIF-dependent pathway is involved in antiviral
responses. TANK-binding kinase 1 (TBK1) and IkB
kinase, inducible (IKKi) were shown to act as IRF3
kinases. TLR7 and TLR9 recognize viral components,
and induce the production of type 1 IFNs. However,
the molecular mechanism is quite different from that of
TLR3- and TLR4-dependent type 1 IFN production.
MyD88 is essential for type 1 IFN production through
TLR7 and TLR9. In various cell types, MyD88-
dependent signalling is associated with inﬂammatory
responses via the activation of NF-kBa n dm i t o g e na c t i -
vated (MAP) kinases. In plasmacytoid dendritic cells
(pDCs) only, TLR7 or TLR9 activation induces the
production of type 1 IFNs via the direct association of
MyD88 with IRF7, independently of TBK1 and IKKi,
in contrast to the case for TRIF-dependent type 1 IFN
production [22].
5. CYTOPLASMIC HELICASES FOR SENSING
OF VIRAL INFECTION
Although the involvement of TLRs in virus-induced
cytokine and IFN production is well established,
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capable of expressing IFN-inducible genes in response
to RNA virus infection, indicating the existence of
TLR-independent virus detectors [23,24]( ﬁgure 3).
An RNA helicase, retinoic acid-inducible gene I
(RIG-I), was identiﬁed as a cytosolic sensor for viral
invasion, and inducestype 1 IFNs in a TLR-independent
manner [25,26]. Melanoma differentiation-associated
gene 5 (MDA5) is homologous to RIG-I. Both heli-
cases possess two N-terminal caspase-recruitment
domains (CARDs) followed by an RNA helicase
domain. The CARDs are responsible for signal trans-
duction, which leads to the activation of NF-kB and
IRF3/7 via their adaptor molecule, IFN-b promoter
stimulator 1 (IPS-1; also called Cardif, MAVS or
VISA), which is located on the outer membrane of
mitochondria [27,28]. TBK1 and IKKi are also
responsible for the activation of RIG-I- or MDA5-
dependent IFN production, indicating that the
signalling pathways triggered by TLR stimulation and
RIG-I converge at the level of TBK1/IKKi. The func-
tional and differential roles of RIG-I and MDA5 were
revealed by gene targeting. RIG-I detects a variety of
RNA viruses by recognizing 50-triphosphate short
dsRNAs or long dsRNAs (several hundred to several
thousand base pairs). On the other hand, MDA5
detects picornavirus family members by recognizing
long dsRNAs of more than 2 kbp [29,30]. RIG-I and
MDA5 are ubiquitously expressed in all cells. DNA
viruses and dsDNAs are also recognized in the cyto-
plasm. Although several candidates for dsDNA
sensors have been reported, essential roles of these
receptors have not been conﬁrmed by gene targeting
and the initial dsDNA recognition mechanism remains
unclear. Recently, stimulator of interferon genes
(STING) was shown to be a mediator of dsDNA-
induced type 1 IFN production [31]. STING is a
multi-spanning membrane protein that associates
with TBK1. STING-deﬁcient cells are hyporesponsive
to dsDNA.
6. NUCLEOTIDE-BINDING DOMAIN-LIKE
RECEPTORS AND C-TYPE LECTIN RECEPTORS
Bacteria are also detected in the cytoplasm by
the members of the nucleotide-binding domain
(NOD)-like receptor (NLR) family (ﬁgure 3). NLRs
consist of a C-terminal LLR domain, a central NOD
and an N-terminal effector domain that initiates sig-
nalling. The minimal components of peptidoglycan
are recognized by NOD1 and NOD2, leading to
NF-kB activation and inﬂammatory response induc-
tion [32]. In addition to NOD1 and NOD2, several
NLRs are present in the cytoplasm. These NLRs are
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Figure 3. C-type lectins, RIG-like receptors (RLRs) and NOD-like receptors. C-type lectins (CLRs) recognize carbohydrates
on micro-organisms via the carbohydrate-binding domain. Dectin-1, Dectin-2, Mincle and CLEC9A are well studied. For
example, Dectin-1 activates the Syk tyrosine kinase via the immunoreceptor tyrosine-based activation motif (ITAM)
domain, resulting in production of inﬂammatory cytokines. RLRs comprise RIG-I and MDA5. RLRs are composed of two
N-terminal caspase-recruitment domains (CARDs), a central DEAD box helicase/ATPase domain, and a C-terminal regula-
tory domain. They are localized in the cytoplasm and recognize the genomic RNA of dsRNA viruses, and dsRNA generated
as the replication intermediate of ssRNA viruses. RLRs interact with IPS1 via their CARD domains, resulting in type 1 inter-
feron production through IKKi/TBK1. NLRs are composed of a central nucleotide-binding domain (NOD) and C-terminal
leucine-rich repeats (LRRs). The N-terminal portions harbour protein-binding motifs. NODs activate caspase-1, resulting in
processing of pro-IL-1b to mature IL-1b.
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duction of mature IL-1 and IL-18 [33]. The
activities of IL-1b and IL-18 are regulated at both
the transcriptional and post-translational levels. Tran-
scriptional activation of these genes leads to the
production of pro-IL-1b and pro-IL-18. These pro-
teins are present in the cytoplasm in inactive forms.
Caspase-1 activation is required for the generation of
mature IL-1b and IL-18, both of which are secreted
from the cytoplasm to the outside of the cell. Inﬂamma-
some formation is essential for caspase-1 activation. At
present, four types of inﬂammasome have been ident-
iﬁed, namely nucleotide-binding domain and leucine-
rich repeat containing family, pyrin domain containing
1 (NLRP1), nucleotide-binding domain and leucine-
richrepeatcontainingfamily,CARDdomaincontaining
4(NLRC4),NLRP3andabsentinmelanoma2(AIM2)
inﬂammasomes, although AIM2 is not a member of the
NOD family. Flagellin (TLR5 ligand) and imidazoqui-
noline/RNA (TLR7 ligands) activate NLRC4 and
NLRP3 inﬂammasomes, respectively. In addition, sev-
eral crystallized molecules, such as monosodium urate,
asbestos and cholesterol crystals, are recognized in the
cytoplasmviatheformationofNLRP3inﬂammasomes.
The ﬂagellin monomer is shaped like the capital Greek
gamma (G) and is formed by domains D0 through D3.
Interestingly, different parts of ﬂagellin are recognized
by TLR5 and NLRC4 inﬂammasomes, since the D1
domain is recognized by TLR5 and the D0 domain is
responsible for NLRC inﬂammasome activation.
b-Glucan is the most abundant cell wall component
of fungi and yeasts. It is also present in bacteria and
plants, but is not found in animals. b-Glucan is recog-
nized by a C-type lectin receptor (CLR), Dectin-1.
Dectin-1 consists of an extracellular carbohydrate-
recognizing C-type lectin domain (CTLD) and a
cytoplasmic tyrosine-containing domain that is similar
to the immunoreceptor tyrosine-based activation motif
(ITAM; ﬁgure 3). Engagement of Dectin-1 by b-
glucan triggers the recruitment of spleen tyrosine
kinase (Syk), which activates NF-kB through CARD9,
Bcl10 and MALT1 as well as caspase-1 [34]. Dectin-1
recognizes several fungal species, including a number
of human pathogens such as Candida, Aspergillus,
Pneumocystis and Coccidioides,a n dp l a y sa ni m p o r t a n t
role in the host defence against these pathogens. Another
CLR, Dectin-2, is predominantly expressed on tissue
macrophages, dendritic cells and inﬂammatory mono-
cytes, and possesses a classical sugar-binding CTLD
that recognizes high-mannose structures in a Ca
2þ-
dependent manner. Using this domain, Dectin-2 recog-
nizes a variety of pathogens including capsule-deﬁcient
Cryptococcus neoformans, Candida albicans, Saccharomyces
cerevisiae, Mycobacterium tuberculosis, Microsporum
audounii, Trichophyton rubrum, Paracoccidioides brasiliensis
and Histoplasmacapsulatum. Although it has a short cyto-
plasmic tail that lacks traditional signalling motifs,
Dectin-2 associates with the ITAM-containing FcRg
adaptor and can trigger intracellular signalling through
the Syk/CARD9 pathway to induce a variety of
mDCs
cytokines
key
effectors
exposed host
pDCs
RIG-I
TLR7
TLR7
flu vaccine
subtypes
formalin
inactivated
live virus
whole virus vaccine
virus RNA
surface antigen
enriched
split vaccine
Th1-type
antibody
IFNg
resultant
adaptive
immune
activation
CD8+T cell
cytotoxicity
CD4+ T cell B cell
memory
CD4+T cell
IFNg
macrophages
type 1 IFNs
proinflammatory cytokines
i
n
n
a
t
e
 
i
m
m
u
n
i
t
y
key
cells and
innate
immune
receptors
pDCs
type 1 IFNs
pDCs
uncertain NLR
epithelial cells
no innate
response
no immunity
innate response
is not necessarily
required
TLR7
viability
naive host
mDCs
a
d
a
p
t
i
v
e
i
m
m
u
n
i
t
y
Figure 4. Induction of adaptive immunity by inﬂuenza viral infection and vaccination. In the case of live inﬂuenza viruses, the
viruses infect a variety of cells except for plasmacytoid dendritic cells (pDC) and produce RNAs, which are recognized by
RIG-I, resulting in type 1 interferon production. pDCs are resistant to infection and phagocytose the viral particle, and
RNA is liberated in the phagolysome, which result in activation of TLR7/MyD88-dependent pathway and type 1 interferon
production. In the case of inactivated whole virus vaccine, this cannot infect but pDCs engulf the inactivated virus, and sub-
sequent activation of TLR7/MyD88-dependent pathway leads to production of type 1 interferon. This pathway is also essential
to induction of adaptive immunity against inﬂuenza virus. Split vaccine lacking RNA is not effective in naive persons but can
play some role in protection by activating memory B cells in people who have already experienced inﬂuenza viral infection.
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(Mincle)isprimarilyexpressedbyactivatedmacrophages.
Similar to Dectin-2, Mincle possesses a single extracellu-
lar CTLD and a short cytoplasmic tail, and associates
with the adaptor FcRg to trigger intracellular signalling
through the Syk/CARD9 pathway. Mincle recognizes a
variety of endogenous and exogenous ligands, such
as necrotic cells (small nuclear ribonucleoprotein
SAP130), mycobacteria (trehalose dimycolate or myco-
bacterial cord factor) and certain fungi (a-mannan),
including Candida, Saccharomyces and Malassezia.
7. INFLUENZA VIRUS AND IMMUNITY
Recent advances in our understanding of innate
immunity have revealed that activation of the innate
immune system is essential for subsequent adaptive
immune responses including speciﬁc antibody pro-
duction and cytotoxic T-lymphocyte activation,
which play key roles in the protection against virus
infection.
In the case of inﬂuenza virus infection or vaccin-
ation with an attenuated live virus, the RIG-I/IPS-1
and TLR7/MyD88 pathways are triggered in tissue-
speciﬁc manners. Speciﬁcally, the RIG-I/IPS-1
pathway is activated in many cell types, but not in
pDCs, while the TLR7/MyD88 pathway induces
type 1 IFN production only in pDCs. In live virus
infection, many cells are infected, viral replication
takes place, and RNA is produced in the cytoplasm
and recognized by RIG-I. Although pDCs are resistant
to infection, the viral particles are incorporated into
the endosome/lysozome, where they are disrupted,
leading to liberation of the RNA and its recognition
by TLR7. On the other hand, the inactivated inﬂuenza
virus used as a vaccine cannot infect cells. Neverthe-
less, pDCs phagocytose the viral particles and type 1
IFNs are produced in a TLR7/MyD88-dependent
manner [35]( ﬁgure 4). There is a tendency to use
puriﬁed components from inﬂuenza virus particles
(subunit vaccines) as vaccines to avoid adverse effects.
A subunit vaccine, Split HA, is now used for seasonal
ﬂu in Japan. However, this product lacks inﬂuenza
virus-derived RNA and does not induce innate
immune responses, and therefore, could not protect
naive mice that had never experienced inﬂuenza virus
infection [36]. The Split HA vaccine may be useful
for adult humans who have experienced repeated ﬂu
infections and have memory T and B cells. When the
Split HA vaccine was injected together with CpG
DNA, this formulation induced both innate and
adaptive immunity against inﬂuenza virus in a
TLR9-dependent manner. These ﬁndings reinforce
the notion that efﬁcient induction of adaptive immu-
nity requires immunostimulatory TLR ligands as
adjuvants in addition to antigens (ﬁgure 4).
8. CONCLUSIONS
Innate immunity is essential for both the development
and modulation of adaptive immunity. Pathogens are
recognized by four types of innate immune-associated
receptors, namely TLRs, NLRs, RIG-like receptors
and CLRs. The initial recognition of pathogens by
these receptors induces inﬂammatory reactions at the
infectedsite,andalsotriggersadaptiveimmunityagainst
the pathogens. We need to clarify more precisely the
immune response pathway, starting from the activation
of innate pathogen receptors, that ﬁnally leads to the
development of protective immunity against individual
pathogens. Such ﬁndings will enable us to develop
rational vaccines.
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